CSIMarket
 
Atyr Pharma Inc   (LIFE)
Other Ticker:  
 
 
Price: $1.9550 $-0.04 -1.759%
Day's High: $2.03 Week Perf: 20.68 %
Day's Low: $ 1.90 30 Day Perf: 1.56 %
Volume (M): 868 52 Wk High: $ 2.70
Volume (M$): $ 1,696 52 Wk Avg: $1.77
Open: $2.03 52 Wk Low: $1.08



 Market Capitalization (Millions $) 113
 Shares Outstanding (Millions) 58
 Employees -
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 5

Atyr Pharma Inc

We are a global biotechnology tools company dedicated to helping our customers make scientific discoveries and ultimately improve the quality of life. Our systems, reagents, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that better the quality of life. Life Technologies customers do their work across the biological spectrum, advancing personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The Company employs approximately 9,700 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses.

Our systems and reagents enable, simplify and accelerate a broad spectrum of biological research of genes, proteins and cells within academic and life science research and commercial applications. Our scientific expertise assists in making biodiscovery research techniques more effective and efficient for pharmaceutical, biotechnology, agricultural, government and academic researchers with backgrounds in a wide range of scientific disciplines.

We offer many different products and services, and are continually developing and/or acquiring others. Some of our specific product categories include the following:

• “High-throughput” gene cloning and expression technology, which allows customers to clone and expression-test genes on an industrial scale.
• Pre-cast electrophoresis products, which improve the speed, reliability and convenience of separating nucleic acids and proteins.
• Antibodies, which allow researchers to capture and label proteins, visualize their location through use of Molecular Probes dyes and discern their role in disease.
• Magnetic beads, which are used in a variety of settings, such as attachment of molecular labels, nucleic acid purification, and organ and bone marrow tissue type testing.
• Molecular Probes fluorescence-based technologies, which facilitate the labeling of molecules for biological research and drug discovery.
• Transfection reagents, which are widely used to transfer genetic elements into living cells enabling the study of protein function and gene regulation.
• PCR and Real Time PCR systems and reagents, which enable researchers to amplify and detect targeted nucleic acids (DNA and RNA molecules) for a host of applications in molecular biology.
• Cell culture media and reagents used to preserve and grow mammalian cells, which are used in large scale cGMP bio-production facilities to produce large molecule biologic therapies.
• RNA Interference reagents, which enable scientists to selectively “turn off” genes in biology systems to gain insight into biological pathways.
• Capillary electrophoresis and massively parallel SOLiDtm DNA sequencing systems and reagents, which are used to discover sources of genetic and epigenetic variation, to catalog the DNA structure of organisms de novo, to verify the composition of genetic research material, and to apply these genetic analysis discoveries in markets such as forensic human identification.
• High performance mass spectrometer systems which are used in numerous applications such as drug discovery and clinical development of therapeutics as well as in basic biological research, food and beverage quality testing, environmental testing, and other applied or clinical research applications.

We divide our target customer base into three major categories:


• Life science researchers. The life sciences research market consists of laboratories generally associated with universities, medical research centers, government institutions such as the United States National Institutes of Health, or the NIH, and other research institutions as well as biotechnology, pharmaceutical, diagnostic, energy, agricultural, and chemical companies. Researchers at these institutions are using our products and services in a broad spectrum of scientific activities, such as: searching for drugs or other techniques to combat a wide variety of diseases, such as cancer and viral and bacterial disease; researching diagnostics for disease identification or for improving the efficacy of drugs to targeted patient groups; and assisting in vaccine design, bioproduction, and agriculture. Our products and services provide the research tools needed for genomics studies, proteomics studies, gene splicing, cellular analysis, and other key research applications that are required by these life science researchers.

• Commercial producers of biopharmaceutical and other high valued proteins. We serve industries that apply genetic engineering to the research and commercial production of useful but otherwise rare or difficult to obtain substances, such as proteins, interferons, interleukins, t-PA and monoclonal antibodies. Once a discovery has been proven, the manufacturers of these materials require larger quantities of the same sera and other cell growth media that we provide in smaller quantities to researchers. Industries involved in the commercial production of genetically engineered products include the biotechnology pharmaceutical, food processing and agricultural industries.

• Users who apply our technologies to enable or improve particular activities. We provide tools that apply our technology to enable or improve activities in particular markets, which we refer to as applied markets. The current focus of our products for these markets is in the areas of: forensic analysis, which is used to identify individuals based on their DNA; quality and safety testing, such as testing required to measure food, beverage, or environmental quality and pharmaceutical manufacturing quality and safety; production animal health testing, which enables the detection of pathogens in livestock; and biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers. The Applied Biosystems branded forensic testing and human identification products and services are innovative and market-leading tools that have been widely accepted by investigators and laboratories in connection with, for example, criminal investigations, the exoneration of individuals wrongly accused or convicted of crimes, identifying victims of disasters, and paternity testing.

Competition

The markets for the products of each of our segments are competitive and are characterized by the application of advanced technologies. New technologies in life sciences could make our products and services obsolete unless we continue to develop new and improved products and services and pursue new market opportunities. Given the breadth of our product and service offerings, our competition comes from a wide array of competitors with a high degree of technical proficiency, ranging from specialized companies that have strengths in narrow segments of the life science markets to larger manufacturers and distributors offering a broad array of biotechnology products and services and have significant financial, operational, research and development, and sales and marketing resources. These and other companies may have developed or could in the future develop new technologies that compete with our products or even render our products obsolete. Additionally, there are numerous scientists making materials themselves instead of using kits. We believe that a company’s competitive position in our markets is determined by product function, product quality, speed of delivery, technical support, price, breadth of product line, distribution capabilities, and timely product development. Our customers are diverse and may place varying degrees of importance on the competitive attributes listed above. While it is difficult to rank these attributes for all our customers in the aggregate, we believe we are well positioned to compete in each category.



   Company Address: 10240 Sorrento Valley San Diego 92121 CA
   Company Phone Number: 731-8389   Stock Exchange / Ticker: NASDAQ LIFE
   


Customers Net Income fell by LIFE's Customers Net Profit Margin grew to

-3.69 %

25.73 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -1.18%    
ABT   -6.89%    
DHR   -0.64%    
HON   -1.19%    
TMO   -2.88%    
• View Complete Report
   



Clinical Study

aTyr Pharma Launches Expanded Access Program for EFZO-FIT Clinical Trial Participants, Suppliers Witness Increased Sales Despite Declining Net Profit Margin.

Published Wed, Feb 21 2024 1:00 PM UTC

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants as Suppliers Report Increase in Sales, but Decline in Net Profit MarginIn an exciting development, aTyr Pharma Inc has announced an Expanded Access Program (EAP) for participants of their EFZO-FIT clinical trial. This program aims to provide access to a potential breakthrough therapy...

Clinical Study

aTyr Pharma Unveils Groundbreaking Research Amid Economic Challenges: Navigating Market Fluctuations with Pioneering Science.

Published Mon, Jan 29 2024 1:01 PM UTC

In the ever-important world of biopharmaceuticals, aTyr Pharma recently made significant headway by shedding light on the crucial role of Neuropilin-2 (NRP2) in immune regulation. The research was presented at the Keystone Symposia on Myeloid Cell Diversity, a prominent confluence of researchers and medical practitioners from across the globe. This event served as a platform...

Atyr Pharma Inc

Atyr Pharma Inc Delivers Impressive Revenue of $0.353 Million, Marking a Resilient Third Quarter in 2023 Financial Report



The stock market has always been a hub of intriguing investment opportunities, and the Biotechnology & Pharmaceuticals sector often attracts considerable attention. A prominent player in this sector, Atyr Pharma Inc, recently disclosed some fascinating financial details that shed light on its recent growth and potential future earnings. Let's delve into these figures and explore their implications for investors.
Revenue and Net Shortfall Figures:
In its most recent fiscal period, Atyr Pharma Inc revealed $0.353 million in Revenue. While this may seem relatively modest at first glance, it is important to consider the company's growth trajectory and its focus on innovative biotechnology and pharmaceutical solutions.

Atyr Pharma Inc

Atyr Pharma's Operating Loss Deepens to $-13.558 Million in Q2 2023 Report, Signaling Uncertainty for Future Prospects



Atyr Pharma Inc, a biotechnology company in the Pharmaceuticals sector, recently reported its financial results for the second quarter of 2023. These results, which include increased operating loss and relatively stable net loss compared to the previous year, raise questions about the company's future prospects and how these figures may impact its overall performance moving forward. Additionally, we will explore the stock's recent decline and its trading position in relation to the 52-week low.
1. Declining Share Performance:
Over the past five trading days, Atyr Pharma Inc shares experienced a 2% decline. This brings the year-to-date performance to a significant -16.95% decrease. While short-term fluctuations are common in the stock market, the negative trend warrants investor attention and implores analysis of potential factors contributing to this decline.

Atyr Pharma Inc

Atyr Pharma Inc Emerges as a Biotech Powerhouse, Unveiling its Momentous First Quarter 2023 Results

As the global Biotechnology & Pharmaceuticals sector reports its financials for the first quarter of 2023, Atyr Pharma Inc, a leading biotechnology company, has released its own numbers. The company's operating shortfall for the first three months of the year was $-12.787 million, which is only slightly higher than the operating shortfall from the same period in 2022, which was $-12.378 million.
While these numbers may appear concerning on the surface, it's essential to understand the context of the overall market and Atyr Pharma Inc's position within it. Biotechnology is an industry that is constantly evolving, and companies must continually adapt to keep up with advancements in research and development.






 

Atyr Pharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com